#1 U.S. CBD Brand and Category Leader
A Return to Growth Under Renewed Leadership
Proposed BAT Recapitalization to Strengthen the Balance Sheet
Positioned to Participate in the CMMI Medicare Pathway
Pharmaceutical Optionality Through DeFloria FDA Phase 2
Innovation Across the Cannabinoid Spectrum
Vertically Integrated, B Corp Certified, Leading with Quality and Science